Retatrutide

Quickstart Highlights

Retatrutide is an investigational triple agonist that activates the GLP-1, GIP and glucagon receptors from a single peptide, with a half-life of roughly 6 days that supports once-weekly dosing. It is being studied for obesity, type 2 diabetes and liver fat reduction; the 48-week Phase 2 trial reported up to 24.2% mean weight loss. This educational protocol presents the Phase 3 once-weekly subcutaneous titration: 2 mg for Weeks 1–4, stepping every 4 weeks to 8 mg by Week 13, then maintenance at 8–12 mg from Week 17 (12 mg is the ceiling, reached only if needed and tolerated), with an optional 0.5–1 mg on-ramp; the 50 mg vial is reconstituted with 3.0 mL (16.67 mg/mL), a derived figure that keeps every dose, including 12 mg, within the V1 pen’s range.

• Reconstitute: Add 3 mL bacteriostatic water → 16.67 mg/mL concentration.
• Dose range: 2–12 mg once weekly, subcutaneously (optional 0.5–1 mg on-ramp): 2 mg for Weeks 1–4, then 4 mg, 6 mg and 8 mg in 4-week steps, then 8–12 mg maintenance from Week 17; 12 mg is the ceiling, reached only if needed and tolerated.
• Easy measuring: At 16.67 mg/mL, 1 unit = 0.01 mL = 166.67 mcg on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 28 days.
• Trial basis: Escalate no faster than every 4 weeks (the trial step length). The optional 0.5–1 mg on-ramp (Weeks 0–2) is a tolerability step for users sensitive to GI side effects, not a dose from the Phase 2 obesity trial (0.5 mg was a fixed arm only in the Phase 2 type 2 diabetes trial); the Phase 2 obesity arms started at 1, 2 or 4 mg and the Phase 3 ladder starts at 2 mg.

Protocol Overview

Concise summary of the once-weekly regimen.

• Goal: Support weight reduction and metabolic improvement through combined GLP-1, GIP and glucagon receptor activation, reducing appetite while raising energy expenditure.
• Schedule: Weekly subcutaneous injections, continuous with no off-cycle: 2 mg for Weeks 1–4, then dose steps every 4 weeks to 8 mg by Week 13 and maintenance at 8–12 mg from Week 17 (optional 0.5–1 mg on-ramp first). Continue until the desired weight is achieved, then hold the maintenance dose or taper under clinical guidance.
• Dose Range: 2–12 mg once weekly (optional 0.5–1 mg on-ramp): 2 mg (2000 mcg) to 8 mg (8000 mcg) in 4-week steps, then 8–12 mg (8000–12,000 mcg) in maintenance; 12 mg is the ceiling, reached only if needed and tolerated.
• Reconstitution: 3 mL per 50 mg vial (16.67 mg/mL) for accurate unit measurements on standard insulin syringes.
• Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 28 days; avoid repeated freeze–thaw cycles.
• Evidence: Human RCT: the once-weekly route, 4-week step length and 4–12 mg targets come from the NEJM Phase 2 trial (n=338, 48 weeks) and Phase 3 TRIUMPH readouts, giving high confidence; the optional 0.5–1 mg on-ramp is a tolerability step for users sensitive to GI side effects, not trial dosing (the Phase 2 arms started at 1, 2 or 4 mg and stepped every 4 weeks), so confidence for those weeks is medium. No source covers a 50 mg vial, so the reconstitution figures here are derived arithmetically rather than taken from a published convention.

Dosing Protocol

Suggested weekly titration following the Phase 3 ladder, with an optional community tolerability on-ramp.

• Optional on-ramp (Weeks 0–2): 0.5–1 mg once weekly for users sensitive to GI side effects, then begin the 2 mg step; 0.5 mg was not used in the Phase 2 obesity trial and 1 mg was its lowest arm.
• Weeks 1–4: 2 mg (2000 mcg) once weekly, the starting dose used in most Phase 2 escalation arms and throughout Phase 3.
• Weeks 5–8: 4 mg (4000 mcg) once weekly; the 4 mg arm produced 17.1% mean weight loss at 48 weeks in Phase 2.
• Weeks 9–12: 6 mg (6000 mcg) once weekly as an intermediate step before maintenance.
• Weeks 13–16: 8 mg (8000 mcg) once weekly; the 8 mg arm produced 22.8% mean weight loss at 48 weeks in Phase 2.
• Week 17+ (maintenance): 8–12 mg once weekly; hold 8 mg as the working maintenance dose and increase toward 12 mg only if needed and tolerated.
• Ceiling: 12 mg once weekly is the highest dose studied and the ceiling of the maintenance range, reached only if needed and tolerated; at 16.67 mg/mL it is 72 units (0.72 mL), which fits a 1 mL syringe and the V1 pen’s 80-unit limit.
• Frequency: Once per week (subcutaneous injection), on the same day each week; never step up faster than every 4 weeks, and if gastrointestinal effects are unmanageable hold the current step for a further 4 weeks rather than stepping back.
• Timing: Any time of day; no evidence-based timing exists. Rotate injection sites to reduce local irritation.
• Cycle: Continuous, once weekly on the same day; no off-cycle. Continue until the desired weight is achieved, then hold the maintenance dose or taper under clinical guidance.

Storage Instructions

Proper storage preserves product quality and efficacy.

• Lyophilized (powder): Store at −20 °C (−4 °F) in a cool, dry place protected from light; sources report 12 months or longer at this temperature. For short-term storage (under a few months), 2–8 °C (35.6–46.4 °F) refrigeration is acceptable.
• Reconstituted (solution): Refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze. Use within 28 days for maximum potency and safety; the benzyl alcohol in bacteriostatic water inhibits bacterial growth, but sources range from 14 to 30 days and solutions should be discarded after approximately 4 weeks.
• Allow vials to reach room temperature before opening to minimize condensation uptake.
• Avoid repeated freeze–thaw cycles and keep the reconstituted vial out of direct light.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a proper sharps container.
• Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and avoid lipohypertrophy.
• Administer on the same day each week for consistency; for a missed dose, sources apply the semaglutide rule of taking it within about 5 days and otherwise skipping to the next scheduled dose.
• The optional 0.5–1 mg on-ramp (Weeks 0–2) is a tolerability step for users sensitive to GI side effects, not trial dosing: the NEJM Phase 2 arms started at 1, 2 or 4 mg and stepped every 4 weeks, and the 2 mg start produced fewer gastrointestinal effects than the 4 mg start with equal weight loss.
• Escalate no faster than every 4 weeks. Compressed schedules (2-week steps or starting above 2 mg) are reported to drive gastrointestinal discontinuation; hold a step for an extra 4 weeks rather than back-titrating if nausea is unmanageable.
• Not approved by Health Canada, the FDA or the EMA; retatrutide is investigational (Phase 3 ongoing) and is sold for research use only.
• Evidence caveat: the 4–12 mg targets are trial-derived, but 8 mg as the working maintenance dose reflects the Phase 2 8 mg arm and community practice; 12 mg is the maximum studied and the ceiling of the 8–12 mg maintenance range, reached only if needed and tolerated, and a dose-dependent resting heart-rate increase was recorded at every trial dose.
• No published source gives a reconstitution for a 50 mg vial; the 3.0 mL figure is derived (50 mg ÷ 3 mL = 16.67 mg/mL, about 167 mcg per unit) so that 1 mg equals 6 units and every dose from the optional 0.5 mg on-ramp (3 units) to the 12 mg ceiling (72 units) sits inside the V1 pen’s 1–80 unit range. Vial yield under the 28-day rule: the first 16 weeks use 80 mg across 4 vials and 24 weeks use 144–176 mg across 6 vials. Reconstituted solution is discarded after 28 days, and at every dose on the table, including the 12 mg ceiling (48 mg per 4 weeks), a 50 mg vial outlasts that window, so each 4-week block opens a new vial and the Supplies counts include the discarded remainder; the 10 mg size is better matched to the optional on-ramp weeks.

How This Works

Retatrutide is a single peptide engineered to activate three incretin-family receptors at once: GLP-1, GIP and glucagon. GLP-1 and GIP agonism suppress appetite, slow gastric emptying and improve glucose-dependent insulin secretion, while glucagon-receptor agonism raises energy expenditure and hepatic fat oxidation. A fatty-acid side chain binds albumin, giving a half-life of roughly 6 days that supports once-weekly dosing. In the 48-week NEJM Phase 2 trial (n=338), mean weight change was −8.7% at 1 mg, −17.1% at 4 mg, −22.8% at 8 mg and −24.2% at 12 mg versus −2.1% with placebo, with gastrointestinal effects concentrated during escalation. Phase 3 TRIUMPH readouts report roughly 28% weight loss at 12 mg over 68–80 weeks and a 1.5-point A1C reduction in type 2 diabetes. This is trial evidence for the weekly route, the 4-week step length and the 4–12 mg targets; it does not validate sub-2 mg starting doses, which remain a community tolerability convention.

Potential Benefits & Side Effects

Observations from Phase 2 and Phase 3 clinical trials.

Potential Benefits:

• Mean weight loss of 8.7% (1 mg), 17.1% (4 mg), 22.8% (8 mg) and 24.2% (12 mg) versus 2.1% with placebo at 48 weeks in the Phase 2 trial.
• Approximately 28% weight loss at 12 mg over 68–80 weeks in the Phase 3 TRIUMPH-1 and TRIUMPH-4 trials.
• A1C reduction of about 1.5 points in type 2 diabetes in the Phase 3 TRIUMPH-2 trial.
• Liver fat reduction of roughly 80% at 8–12 mg in the Phase 2 MASH sub-study.
• Reduced appetite and food noise, with improved glucose tolerance and lipids, reported across trial and community sources.

Potential Side Effects:

• Gastrointestinal effects (most common): nausea in 26–45% of trial participants (up to 60% at 12 mg in Phase 3), vomiting 16–28%, diarrhea 18–25% and constipation 16–24%; dose-related and concentrated during escalation.
• Dose-dependent resting heart-rate increase of 5–11 bpm, peaking around week 24 and then declining.
• Dysesthesia or cutaneous hyperesthesia (skin sensitivity) in 7% of Phase 2 participants versus 1% with placebo, and about 21% at 12 mg in Phase 3.
• Injection-site reactions (6–9%) and fatigue in the early weeks.
• Discontinuation for adverse events in 6–16% of trial participants versus 0% with placebo; GLP-1 class cautions apply (pancreatitis, gallbladder disease, thyroid C-cell warning by class, not for use in pregnancy).

Lifestyle Factors

Complementary strategies for optimal outcomes with incretin-based therapy.

• Maintain a calorie-controlled diet with adequate protein intake (1.2–1.6 g/kg body weight) to preserve lean muscle mass during rapid weight loss.
• Combine resistance training (2–3 days per week) with aerobic exercise (150+ minutes per week) to protect muscle and reinforce metabolic adaptations.
• Eat smaller, slower meals and limit high-fat foods during escalation weeks, when nausea is most likely.
• Stay well hydrated (8–10 glasses of water daily), particularly if vomiting or diarrhea occurs.
• Prioritize consistent sleep (7–9 hours nightly) and effective stress management to support adherence.
• Track weight, resting heart rate and any skin sensitivity weekly, and review progress with a healthcare provider.

Injection Technique

General subcutaneous injection guidance from clinical best-practice resources.

• Clean the vial stopper and chosen skin site with separate alcohol swabs; allow both to dry completely before proceeding.
• Pinch a fold of skin between your fingers; insert the needle at a 45–90° angle into the subcutaneous tissue (fatty layer, not muscle).
• Do not aspirate (pull back the plunger) when giving a subcutaneous injection.
• Inject the solution slowly and steadily; wait at least 6 seconds after injection before withdrawing the needle to ensure complete delivery and minimize leakage.
• Withdraw the needle and apply light pressure with a clean swab; avoid rubbing vigorously.
• Rotate injection sites systematically (abdomen, thighs, upper arms) to prevent lipohypertrophy and maintain consistent absorption.
• Dispose of used syringes and needles immediately in a proper sharps container.

Recommended Source

We recommend Amino Labs for high-purity Retatrutide (50 mg vials).

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

Shop at Amino Labs